Table 2.
Progression-Free Survival from initiation of PRRT.
| Krenning Score | WHO Grade | SUVmax Pretreatment | Cumulative Dose (GBq) | Best Radiologic Response | PFS 2D RANO Criteria |
|
|---|---|---|---|---|---|---|
| 1 | 3 | II | 7.4 | 10.6 | PD | 2 months |
| 2 | 3 | II | 26.3 | 29.6 | SD | 10 months |
| 3 | 3 | II | 45 | 29.6 | SD | 17 months |
| 4 | 2 | II | 14.5 | 29.6 | SD | 16 months |
| 5 | 2 | III; II | 12.3 | 29.6 | SD | not reached at 12 months |
| 6 | 3 | II | 16 | 29.6 | SD | not reached at 9 months |
| 7 | 3 | II | 16.8 | 29.6 | SD | N/A * |
| 8 | 3 | II | 15.4 | 29.6 | SD | not reached at 16 months |
DOTATOC PET scans were graded using Krenning score (0 = no uptake; 1 = very low; 2 = equal to liver; 3 = greater than liver; 4 = greater than spleen. * MRI has not been performed during follow-up for patient 7. The 68Ga-DOTATOC lesion volumetry during follow-up was stable, but the patient was excluded from the PFS-6 analysis based on bidimensional RANO criteria on the MRI.